9AVR image
Deposition Date 2024-03-04
Release Date 2024-10-23
Last Version Date 2025-05-07
Entry Detail
PDB ID:
9AVR
Title:
Human eIF4A-1 in complex with AMP-PNP, RNA, and the inhibitor silvestrol
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Host Organism:
Method Details:
Experimental Method:
Resolution:
1.91 Å
R-Value Free:
0.19
R-Value Work:
0.14
R-Value Observed:
0.15
Space Group:
P 21 21 21
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Eukaryotic initiation factor 4A-I
Gene (Uniprot):EIF4A1
Chain IDs:A
Chain Length:406
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polyribonucleotide
Molecule:RNA oligonucleotide (AG)5
Chain IDs:B
Chain Length:10
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
Protein-RNA interactions mediated by silvestrol-insight into a unique molecular clamp.
Nucleic Acids Res. 52 12701 12711 (2024)
PMID: 39351865 DOI: 10.1093/nar/gkae824

Abstact

Molecular staples or interfacial inhibitors are small molecules that exert their activity through co-association with macromolecules leading to various effects on target functions. Some molecules inhibit target activity, while others generate gain-of-function complexes. We and others have previously identified two structurally distinct classes of molecular staples, pateamine A and rocaglates. These molecules inhibit eukaryotic initiation factor (eIF) 4A, a critical RNA helicase required for translation initiation, by simultaneously interacting with both RNA and protein components. Structural insights from members of these two families indicate that they wedge themselves between RNA bases during engagement. To extend our understanding of rocaglates, we investigated the RNA-binding properties of silvestrol, a natural rocaglate distinguished by the presence of a unique dioxanyloxy ring. Our study demonstrates that silvestrol expands the RNA-binding repertoire of rocaglates due to this structural characteristic, providing a rationale for improving synthetic molecular staples targeting eIF4A.

Legend

Protein

Chemical

Disease

Primary Citation of related structures